BMS turns to mechanistic diversity in early oncology pipeline
BMS has holes to fill with upcoming patent expirations
BMS has holes to fill with upcoming patent expirations.
As BMS builds out its early pipeline to find its next big act in cancer and head off revenue losses from upcoming patent cliffs, it’s taking a broad sweep across oncology’s hottest target spaces and technologies to see what sticks.
Now that the dust has settled on its 2019 acquisition of Celgene Corp., Bristol Myers Squibb Co. (NYSE:BMY) has to integrate the assets into its pipeline. It also has to work the series of deals it’s made since then and the investment in internal R&D into a portfolio that will yield revenue drivers as patent expirations for its top three sellers — Revlimid lenalidomide, Eliquis apixaban and Opdivo nivolumab — begin between one and eight years from now.
Together, the three drugs accounted for over $18 billion in sales in 2020.
BMS’ $13.1 billion November acquisition of Myokardia Inc. for its cardiovascular pipeline could start to fill the hole, with Phase III hypertrophic cardiomyopathy candidate mavacamten headed for an NDA submission this quarter. BMS expects it to be a multi-billion-dollar